المؤلفون: J. Mazieres, T.M. Kim, B.K. Lim, M. Wislez, C. Dooms, G. Finocchiaro, H. Hayashi, C.K. Liam, J. Raskin, L.M. Tho, F. de Marinis, E. Nadal, E. Smit, X. Le, S. Brutlach, A.M. O'Brate Grupp, S. Adrian, B. Ellers-Lenz, N. Karachaliou, Y-L. Wu

المصدر: Annals of Oncology. 33:S1419-S1420

مصطلحات موضوعية: Oncology, Hematology

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::a71b374d775de40c5d3feb5aad51fa7d
https://doi.org/10.1016/j.annonc.2022.08.054

المؤلفون: O. Schönborn-Kellenberger, Arnulf Stenzl, N. Halama, Sven D. Koch, Ulrike Gnad-Vogt, M. M. Hipp, M. Fotin-Mleczek, Susan Feyerabend, Hubert Kübler, H.S. Hong, A. Schroeder, Margitta Retz, S. Brutlach, M. Scholl, U. Klinkhardt, F. Doener, T. Seibel, Carsten Grüllich

المصدر: Annals of Oncology. 28:v410

مصطلحات موضوعية: Brachial Plexus Neuritis, Oncology, medicine.medical_specialty, Messenger RNA, business.industry, Prostatectomy, medicine.medical_treatment, Hematology, medicine.disease, Prostate cancer, Cancer immunotherapy, Internal medicine, Medicine, In patient, Open label, business

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::7da1bd5d24f9dafda31e37c0458022f0
https://doi.org/10.1093/annonc/mdx376.020

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

المؤلفون: F Smit E; Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Dooms C; Department of Respiratory Diseases & Respiratory Oncology Unit, University Hospitals Leuven, Leuven, Belgium., Raskin J; Department of Pulmonology & Thoracic Oncology, Antwerp University Hospital (UZA), Edegem, Belgium., Nadal E; Department of Medical Oncology, Catalan Institute of Oncology, L'Hospitalet, Barcelona, Spain., Tho LM; Department of Oncology, Pantai Hospital, Kuala Lumpur, Malaysia., Le X; Department of Thoracic Head & Neck Medical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA., Mazieres J; CHU de Toulouse, Institut Universitaire du Cancer, Toulouse, France., S Hin H; Hospital Tengku Ampuan Afzan, Pahang, Malaysia., Morise M; Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan., W Zhu V; University of California Irvine, Chao Family Comprehensive Cancer Center, Orange, CA, USA., Tan D; Division of Medical Oncology, National Cancer Centre Singapore, Singapore., H Holmberg K; EMD Serono Research & Development Institute, Inc., MA, USA, an affiliate of Merck KGaA., Ellers-Lenz B; Department of Biostatistics, Merck Healthcare KGaA, Darmstadt, Germany., Adrian S; Global Clinical Development, Merck Healthcare KGaA, Darmstadt, Germany., Brutlach S; Late Stage Development Operations, Merck Healthcare KGaA, Darmstadt, Germany., Schumacher KM; Global Clinical Development, Merck Healthcare KGaA, Darmstadt, Germany., Karachaliou N; Global Clinical Development, Merck Healthcare KGaA, Darmstadt, Germany., Wu YL; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China.

المصدر: Future oncology (London, England) [Future Oncol] 2022 Mar; Vol. 18 (9), pp. 1039-1054. Date of Electronic Publication: 2021 Dec 17.

نوع المنشور: Clinical Trial Protocol; Journal Article

بيانات الدورية: Publisher: Future Medicine Ltd Country of Publication: England NLM ID: 101256629 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-8301 (Electronic) Linking ISSN: 14796694 NLM ISO Abbreviation: Future Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Acrylamides*/administration & dosage , Acrylamides*/therapeutic use , Aniline Compounds*/administration & dosage , Aniline Compounds*/therapeutic use , Antineoplastic Agents*/administration & dosage , Antineoplastic Agents*/therapeutic use , Carcinoma, Non-Small-Cell Lung*/drug therapy , Carcinoma, Non-Small-Cell Lung*/mortality , Carcinoma, Non-Small-Cell Lung*/secondary , Drug Resistance, Neoplasm* , Lung Neoplasms*/drug therapy , Lung Neoplasms*/mortality , Lung Neoplasms*/pathology , Neoplasm Metastasis* , Piperidines*/administration & dosage , Piperidines*/therapeutic use , Pyridazines*/administration & dosage , Pyridazines*/therapeutic use , Pyrimidines*/administration & dosage , Pyrimidines*/therapeutic use, Humans ; Antineoplastic Combined Chemotherapy Protocols ; Progression-Free Survival ; Multicenter Studies as Topic ; Clinical Trials, Phase II as Topic